

2 February 2016

Shareholder Update

Highlights

- Omniblend Innovation's flagship product, a patented food-grade pre-meal drink for managing type 2 diabetes (T2D), is to be launched by Faulding under the trade name GlucoControl
- GlucoControl is currently in its initial manufacturing run in Australia
- Offering people with T2D a unique management option, GlucoControl is clinically proven to reduce Glycemic Index (GI) spikes by 35% in people with T2D following high GI meal consumption
- Significant global market opportunity, with over 387m people with T2D and diabetes accounts for 12% of global health expenditure >USD673 billion
- Product launch expected in current quarter, via Australian and New Zealand distribution agreement with Faulding to distribute across Australia's 5,600 pharmacy channels
- Multiple opportunities for expansion into new regions are progressing, including the key priority market of China with over 113m people living with T2D and around half its adult population having pre-diabetes

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on Omniblend Innovation, the medical technology company focused on foods for special medical purposes, in which EVE is acquiring a ~40% holding, subject to certain conditions (see ASX announcement on 17 December 2015).

Omniblend Innovation's flagship product is advancing rapidly towards commercialisation. The product, GlucoControl is a patented food-grade pre-meal drink for managing type 2 diabetes (T2D).

Product Launch in Australia & New Zealand in current quarter

Omniblend Innovation has an Australian and New Zealand distribution agreement in place with Endeavor Health Care (Faulding's brand owner), a leading pharmacy healthcare solutions provider, to distribute the product across 5,600 pharmacy channels. The product will be marketed under the Faulding's brand "GlucoControl" with the product launch expected in the current quarter.



With over 3 million Australians living with T2D or pre-diabetes (a figure that is growing at around 3% per year), Australia is an important near term commercialisation opportunity for the technology.

Clinical Validation

GlucoControl has been clinically proven to reduce Glycemic Index (GI) spikes by 35% in people with T2D when taken prior to the consumption of high GI meals. It contains 5 grams of soluble-fibre and enhances feelings of fullness, without causing weight gain.

These clinical results were achieved by the highly prestigious and pioneering Baker IDI Heart and Diabetes Institute in Melbourne. Additional clinical studies were completed at the Royal Adelaide Hospital's Centre for Research Excellence in Translating Nutritional Science to Good Health to independently confirm the product's efficacy.

These clinical results provide people living with T2D a proven and unique management option for their diabetes, enabling them to choose from a significantly enhanced range of foods without risking high spikes in their blood glucose levels.

Significant Market Opportunity & Multiple Expansion Opportunities

Globally, there are over 387m people living with T2D, Diabetes accounts for 12% of global health expenditure >USD673 billion. Additionally, there are over 280 million people globally who have pre-diabetes (a medical precursor to T2D where patients have impaired glucose tolerance). Sources: International Diabetes Federation, the International Diabetes Federation Diabetes Atlas Key Findings 2015.

Omniblend Innovation is progressing multiple opportunities for expansion into new geographic regions, with China representing a key priority market for GlucoControl. China has over 113m people living with T2D and estimates indicate that around half of all Chinese adults have pre-diabetes, putting them at high risk of diabetes (Source: AsianScientist, Sep. 17, 2014).

The Omniblend Innovation management team is currently in later stage discussions with a number of commercialisation partners in various parts of China. Omniblend Innovation's Managing Director, Arie Nudel is also Principal of Omniblend Nourish, the infant formula company that has successfully established a market exporting Australian made dairy nutritional products into China.

Commenting on the Omniblend Innovation opportunity, Ben Rohr, Investment Director of EVE Investments said:

"With the GlucoControl product launch expected in the first quarter of 2016, and advanced discussions in progress for a registration and distribution partner in China, Omniblend Innovation offers investors a compelling investment opportunity. Following in the footsteps of other successful brands, such as Blackmores and Omniblend Nourish, that have seen rapid adoption in China and other regional markets, we expect Omniblend Innovation to become a significant global healthcare company."

-ENDS-

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au

Justin Kelly
Media & Capital Partners
0408 215 858
justin.kelly@mcpartners.com.au

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au